Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Summary

Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Mild Cognitive Impairment
• Alzheimer's Disease
• Alzheimer's Disease, Early Onset
• Memory Loss
• Memory Disorders
• Memory Impairment

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

60 to 90 years

Sex

All

Healthy volunteers

Accepted

Sponsor

GAP Innovations, PBC

Last updated on ClinicalTrials.gov

April 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites